Microdosing and anxiety: what research says

"Microdosing for anxiety" is one of the most searched phrases around psilocybin. That makes sense: stress and worry are part of modern life, and people look for ways to feel steadier. But between online testimonials and actual evidence there is a gap. Let's look at it honestly.

The short answer: research has not shown that microdosing psilocybin treats or relieves anxiety. Some people say they feel calmer, others feel more nervous, and in placebo-controlled studies people who took a placebo reported similar changes. If anxiety affects your daily life, the right step is to talk to a doctor.

Everyday stress is not an anxiety disorder

Feeling tense before a deadline or unsettled after a rough week is part of being human. An anxiety disorder is something else: a health condition, with persistent symptoms that weigh on daily life, which deserves a proper diagnosis and professional support.

So let's be clear. Microdosing is not a treatment for anxiety disorders, and our truffles are not intended to treat, relieve or prevent any condition. If anxiety is getting in the way of your life, the right first step is a conversation with your GP or a mental health professional. Why a microdose is not comparable to clinical psilocybin research is explained in microdosing is not therapy.

What people report

In surveys, some people who microdose describe feeling calmer, more present, or less caught up in their thoughts. Others report the opposite: a little more nervous, restless or sensitive, especially on the day they take a dose. Psilocybin acts on serotonin receptors, and even at low doses, reactions vary from one person to the next.

These are subjective experiences. They are worth listening to, but they are not results, and they are certainly not guarantees. For an overview of less pleasant reactions, see microdosing side effects and who should not microdose.

What the studies show

Surveys and observational studies

Much of the early work on microdosing relied on online questionnaires completed by people who already microdose. Participants often reported feeling better overall. The catch: they knew what they were taking, most expected it to help, and there was no placebo group. These studies are useful for generating hypotheses, not for proving anything.

Double-blind, placebo-controlled studies

In 2021, a team led by Szigeti published an original "self-blinding" study: participants prepared their own capsules, some containing a microdose and some a placebo, without knowing which was which. Well-being and mood-related scores improved over the weeks in both groups, with no meaningful difference between microdose and placebo. Other placebo-controlled studies with psilocybin published in 2022 reached broadly similar conclusions.

Laboratory research also explores how psychedelics may affect brain plasticity, but mostly at higher doses and often in animals. It would be premature to draw conclusions about microdoses in humans.

What that means

Expectation, ritual and the simple fact of paying attention to yourself play a large role in what people feel. That isn't nothing, but it isn't a proven effect of psilocybin either. The data remain preliminary, and research continues. We review the studies in what research says about microdosing, and its limits.

How to read research on microdosing and anxiety

Headlines on this topic often mix up very different studies. Before drawing any conclusion from an article, check a few points:

• Who took part? Most microdosing studies involve people from the general population, not people diagnosed with an anxiety disorder. A change on a well-being questionnaire says nothing about a health condition.
• What dose? Clinical trials with psilocybin use high doses, with careful screening and professional support. Their results cannot be transferred to a microdose taken at home.
• Was there a placebo? Without one, expectations and the natural ups and downs of anxiety over time can look like an effect.
• How long, and how many? Studies so far are mostly short and small, and long-term data are missing.
• What words are used? "May", "could" and "associated with" describe hypotheses, not results.

Placebo, expectations and anxiety

Expectations are powerful whenever a subject touches on how we feel. Deciding to try something, preparing it carefully and paying attention to your mood can all change how you describe your days. That is part of why placebo groups in microdosing studies often report improvements too.

The reverse also exists. Expecting side effects can make people more aware of every sensation, sometimes called the nocebo effect. For someone prone to worry, a racing heart after a coffee or a restless night can easily be read as a reaction to a dose. One more reason to read your own experience with some distance. For a general picture of what people report, see what a microdose can feel like.

If you're considering it

A few principles, calmly stated:

• If you have a diagnosed anxiety disorder or take medication (especially antidepressants), talk to your doctor first, and never stop or change a treatment on your own. Read also microdosing and antidepressants: interactions and precautions.
• Know that it can go the other way. Some people feel more on edge, not less. If that happens, stop.
• Keep it simple and sober. A calm setting, no alcohol, and no other substances.
• Write things down. A short daily note on sleep, mood and energy helps you see clearly and gives your doctor facts rather than impressions. Tips in keeping a microdosing journal.

The foundations still matter most

Whatever you decide about microdosing, the basics remain the basics: sleep, movement, time outdoors, people you trust, and professional support when things feel too heavy. None of them makes headlines. All of them deserve a place before anything else.

When to seek help

Some situations call for professional support rather than self-experimentation:

• anxiety that lasts, keeps you from working, sleeping or seeing people, or comes with panic attacks;
• worry that gets worse after a dose, or does not settle;
• any thought of harming yourself.

In these cases, talk to your GP or a mental health professional. If you feel in immediate danger, contact your local emergency services. Stopping microdosing is always an option; stopping or changing a prescribed treatment is not something to do on your own.

The bottom line

Microdosing and anxiety is an open research question, not an answer. We'd rather tell you that plainly than sell you a promise.

Important Microdosing is for adults only (18+). It is not recommended during pregnancy or breastfeeding, if you or a close family member have a history of psychotic or bipolar disorders, if you have a heart condition, or if you take any medication, especially antidepressants or lithium. Do not drive, do not combine with alcohol, and talk to a doctor first.

Psilocybin truffles are sold legally in the Netherlands, where BIEN is based. Their status varies from country to country: check the law in your country.

FAQ

Is psilocybin effective for treating anxiety?

No such effect has been established for microdosing, and our truffles are not intended to treat any condition. Clinical research with high doses in medical settings is a different subject. If anxiety is affecting you, talk to a doctor.

Can microdosing make anxiety worse?

Some people report feeling more nervous, restless or sensitive, especially on the day they take a dose. If that happens, stop and talk to a doctor.

Can I microdose if I take medication for anxiety?

Talk to your doctor first. Interactions between psilocybin and some medications, especially antidepressants, are a real concern, and you should never stop or change a treatment on your own.

Is microdosing the same as psilocybin therapy?

No. Clinical studies use much higher doses, with screening and professional support. A microdose taken at home is a different practice.

Sources

• Szigeti B. et al. (2021), Self-blinding citizen science to explore psychedelic microdosing, eLife.
• European Union Drugs Agency (EUDA): information on drugs in Europe.
• PubMed: studies on microdosing, database of the U.S. National Library of Medicine.